GOOD SYNDROME PRESENTING WITH PROGRESSIVE MUSCLE WEAKNESS FOLLOWING THYMECTOMY
Vol. 4 Núm. 3 (2024), Artículos originales
Vol. 4 Núm. 3 (2024)

GOOD SYNDROME PRESENTING WITH PROGRESSIVE MUSCLE WEAKNESS FOLLOWING THYMECTOMY

Artículos originales
https://doi.org/10.17811/ap.v4i3.22228
Publicado 2025-01-09
Ricardo Gómez de la Torre
Internal Medicine Department, Autoimmune Diseases Unit, Central University Hospital of Asturias, Oviedo, Spain
María Folgueras Gómez
Internal Medicine Department, Carmen and Severo Ochoa Hospital, Cangas del Narcea, Asturias, Spain
Lourdes Sánchez Miranda
Neurology Department, Neuromuscular Diseases Unit, Central University Hospital of Asturias, Oviedo, Spain
Ariana Fonseca Mourelle
Hematology Department, Central University Hospital of Asturias, Oviedo, Spain
Iván Fernández Vega
Pathology Department, Central University Hospital of Asturias, Oviedo, Spain
Germán Moris de la Tassa
Neurology Department, Neuromuscular Diseases Unit, Central University Hospital of Asturias, Oviedo, Spain
PDF

Palabras clave

Síndrome de Good
timoma
miopatía por cuerpos de inclusión
aplasia pura de células rojas Good syndrome
thymoma
inclusion body myopathy
pure red cell aplasia

Cómo citar

Gómez de la Torre, R., Folgueras Gómez, M., Sánchez Miranda, L., Fonseca Mourelle, A., Fernández Vega, I., & Moris de la Tassa, G. (2025). GOOD SYNDROME PRESENTING WITH PROGRESSIVE MUSCLE WEAKNESS FOLLOWING THYMECTOMY. Archivos De Patologia, 4(3), 4–9. https://doi.org/10.17811/ap.v4i3.22228
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Descargar cita

Endnote/Zotero/Mendeley (RIS) BibTeX

Resumen

We present the case of a patient with Good syndrome who developed progressive muscle weakness following thymectomy. Muscle biopsy revealed criteria consistent with inclusion body myositis. Throughout her illness, she developed pure red cell aplasia, respiratory failure, and recurrent respiratory infections. She was treated with intravenous immunoglobulins, pyridostigmine, and cyclosporine A, achieving stability in her hematologic condition but without improvement in her myopathic symptoms. This case highlights the potential role of the thymus in the pathogenesis of autoimmune manifestations.

https://doi.org/10.17811/ap.v4i3.22228
PDF

Citas

Kelesidis T, Yang O. Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence. Clin Immunol 2010;135(3):347-63. doi: 10.1016/j.clim.2010.01.006.

Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5: S260-5. doi: 10.1097/JTO.0b013e3181f1f62d.

Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB,et al. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. J Thorac Oncol 2018;13:436-46. doi: 10.1016/j.jtho.2017.11.118

Guevara-Hoyer K, Fuentes-Antrás J, Calatayud Gastardi J, Sánchez-Ramón S. Immunodeficiency and thymoma in Good syndrome: Two sides of the same coin. Immunol Lett 2021;231:11-07. doi: 10.1016/j.imlet.2020.12.010.

Uy K, Levin E, Mroz P, Li F, Shah S. A Rare Complication of Thymoma: Pure White Cell Aplasia in Good's Syndrome. Case Rep Hematol2019; 13:1024670. doi: 10.1155/2019/1024670.

Gurnari C, Durrani J, Pagliuca S, Kishtagari A, Awada H, Kerr CM, et al. Novel invariant features of Good syndrome. Leukemia2021; 35:1792-6. doi: 10.1038/s41375-020-01114-z.

Sakuma H, Yoshida H, Kasukawa R, Satoh N, Yoshino K. An autopsy case with Good's syndrome and dermatomyositis. Clin Rheumatol1985; 4:196-201. doi: 10.1007/BF02032294

Frith J, Toller-Artis E, Tcheurekdjian H, Hostoffer R. Good syndrome and polymyositis. Ann Allergy Asthma Immunol 2014; 112:478. doi:10.1016/j.anai.2014.03.001.

Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics 2018; 15:995-1005. doi: 10.1007/s13311-018-0658-8.

Lilleker JB, Naddaf E, Saris CGJ, Schmidt J, de Visser M, Weihl CC; 272ndENMC workshop participants. 272nd ENMC international workshop: 10 Years ofprogress - revision of the ENMC 2013 diagnostic criteria for inclusion bodymyositis and clinical trial readiness. 16-18 June 2023, Hoofddorp, The Netherlands. Neuromuscul Disord 2024; 37:36-51. doi:10.1016/j.nmd.2024.03.001.